Anaplastic Astrocytoma - A Pipeline Analysis Report | Technavio
LONDON--(BUSINESS WIRE)--May 14, 2018-- presents its latest pipeline analysis report on the market. The report includes an in-depth analysis of the pipeline molecules under investigation within the defined data collection period to treat anaplastic astrocytoma.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180514005740/en/
Technavio has published a new pipeline analysis report on the global anaplastic astrocytoma market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This new report will offer an insight into several factors, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market during the forecast period.
Anaplastic astrocytoma- market overview and forecast
is an uncommon malignant brain tumor. Astrocytomas are the tumors, which are created by some star-molded brain cells that are called astrocytes. Astrocytes and similar cell-shaped tissues encompass and secure other nerve cells, which are found in the brain and the spinal cord. These cells are known as glial cells and the tissues they form are called glial tissues. Tumors that emerge from glial tissues, including astrocytomas are collectively called gliomas.
According to a senior analyst at Technavio for , “The symptoms of anaplastic astrocytoma shift contingent on the area and the size of the tumor. The cause of this tumor is obscure. The side effects of anaplastic astrocytoma vary depending on the location and the size of the tumor. Most indications result from increased pressure within the brain. Anaplastic astrocytoma usually grows slowly, but after some time it may grow quickly.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Anaplastic astrocytoma market segmentation
This market research report segments the market based on therapies employed (monotherapy and combination therapy), RoA (oral, IV, intra-arterially, oral+IV, and unspecified), types of molecules used (small molecule, biomolecule, monoclonal, and vaccine), targets for drugs under development (ornithine decarboxylase, thymidine kinase, caspase-3, EGFRvlll, immune suppressive myeloid cells, EGFR, mTOR and RCC, aurora A kinase, ErbB, LRP-1, pan-KIT and pan-PDGFRa, ERK-5, JAK-2 and FLT-3, and unspecified), and recruitment status (recruiting, completed, active not recruiting, not yet recruiting, and unspecified).
Monotherapy is the use of a single drug to treat a disorder or a disease. In the current pipeline, 47% of all the molecules that are being invested are monotherapy.
Small molecules are chemically manufactured active substances that can enter the cells easily because they have a lower molecular weight of less than 900 Da. Around 53% of the types of molecules used to belong to the small molecules category.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180514005740/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: TECHNOLOGY OTHER TECHNOLOGY RESEARCH OTHER SCIENCE SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/14/2018 09:35 AM/DISC: 05/14/2018 09:35 AM